AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TruSpine Technologies Plc

Report Publication Announcement Sep 30, 2024

10307_rns_2024-09-30_52fa3af5-9f69-442c-82d5-9b52e57f62c8.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 2265G

TruSpine Technologies PLC

30 September 2024

TruSpine Technologies plc

("TruSpine" or the "Company")

Investor Presentation

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering "screwless," spinal (vertebral) stabilisation systems, is pleased to announce that Geoffrey Miller and Samuel Ogunsalu, directors of the Company, will provide a live presentation relating to the Final Results via Investor Meet Company on 8 October 2024, 09:30 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 7 October 2024, 09:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet TruSpine Technologies plc via:

https://www.investormeetcompany.com/truspine-technologies-plc/register-investor

Investors who already follow TruSpine Technologies plc on the Investor Meet Company platform will automatically be invited.

The Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Investor Hub https://investorhub.truspinetech.com
TruSpine Technologies Plc Tel: +44 (0)20 7118 0852
Geoff Miller, Non-executive Chairman
Peterhouse Capital Limited (Broker & Financial Adviser) Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Novus Communications (PR and IR) Tel: +44 (0)1273 704 473
Alan Green / Jacqueline Briscoe [email protected]

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRALMMPTMTBJMLI

Talk to a Data Expert

Have a question? We'll get back to you promptly.